Abstract
Adjuvant radiotherapy (RT), the standard of care for women diagnosed with invasive ESBC after breast-conserving surgery (BCS), is shown to reduce the risk of recurrence for most women; however, it can be associated with major adverse effects including lung/cardiac/breast toxicity. Recently, the POLAR signature was reported to successfully identify women who would or would not benefit from RT after BCS. This study evaluated the cost-effectiveness of the POLAR signature for guiding RT omission compared to RT for all women with hormone receptor-positive (HR+), HER2-negative stage I/IIA breast cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
